Evidence map›Paper›PMID 42395119›Full record

ArticleAnnals of gastroenterological surgery2026

Survival Outcomes of Gemcitabine-Cisplatin-S-1 Versus Gemcitabine-Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion Surgery.

Hisashi Kosaka, Masahiko Kinoshita, Satoshi Yasuda, Satoru Kakizaki, Rie Sugimoto, Jun Sakata, Kiyonori Yamai, Takeshi Hatanaka, Yusuke Yamamoto, Toshifumi Sato and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of gastroenterological surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Hisashi KosakaDepartment of Hepatobiliary Surgery Kansai Medical University Hirakata Japan.
Masahiko KinoshitaDepartment of Hepatobiliary-Pancreatic Surgery Osaka Metropolitan University Osaka Japan.ORCID https://orcid.org/0000-0002-6716-6377
Satoshi YasudaDepartment of Surgery Nara Medical University Kashihara Japan.ORCID https://orcid.org/0000-0003-4323-7422
Satoru KakizakiDepartment of Clinical Research NHO Takasaki General Medical Center Takasaki City Japan.
Rie SugimotoDepartment of Hepato-Biliary-Pancreatology NHO Kyushu Cancer Center Fukuoka Japan.
Jun SakataDivision of Digestive and General Surgery Niigata University Graduate School of Medical and Dental Sciences Niigata City Japan.ORCID https://orcid.org/0000-0003-1773-0133
Kiyonori YamaiDepartment of Gastroenterology, Hematology and Oncology Odate Municipal General Hospital Odate City Japan.
Takeshi HatanakaDepartment of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan.
Yusuke YamamotoDepartment of Surgery Kyoto Prefectural University of Medicine Kyoto Japan.ORCID https://orcid.org/0000-0002-8740-8468
Toshifumi SatoDepartment of Gastroenterology Saiseikai Niigata Hospital Niigata Japan.
Toru IshikawaDepartment of Gastroenterology Saiseikai Niigata Hospital Niigata Japan.
Takanori MorikawaDepartment of Surgery Miyagi Cancer Center Natori City Japan.
Jun HanaokaDepartment of Gastroenterological Surgery Ehime Prefectural Central Hospital Matsuyama City Japan.
Haruki MoriDepartment of Surgery Shiga University of Medical Science Otsu City Japan.ORCID https://orcid.org/0000-0001-9143-256X
Hidenori ToyodaDepartment of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki City Japan.
Tsuyoshi SanukiDepartment of Gastroenterology Hyogo Prefectural Harima-Himeji General Medical Center Himeji City Japan.
Misaki YokoiDepartment of Gastroenterology Hyogo Prefectural Harima-Himeji General Medical Center Himeji City Japan.
Hiroyuki ShibataDepartment of Clinical Oncology Akita University Graduate School of Medicine Akita City Japan.
Koji FukudaDepartment of Clinical Oncology Akita University Graduate School of Medicine Akita City Japan.
Kazuhito KawataHepatology Division, Department of Internal Medicine II Hamamatsu University School of Medicine Hamamatsu City Japan.
Koji AmayaDepartment of Surgery Toyama Prefectural Central Hospital Toyama Japan.
Takashi ItoThird Department of Internal Medicine, Division of Gastroenterology and Hepatology Kansai Medical University Osaka Japan.
Masaaki HidakaDigestive and General Surgery Shimane University Faculty of Medicine Matsue Japan.ORCID https://orcid.org/0000-0001-8191-6405
Atsushi NaganumaDepartment of Gastroenterology NHO Takasaki General Medical Center Takasaki Japan.
Keishi SugimachiDepartment of Hepatobiliary and Pancreatic Surgery NHO Kyushu Cancer Center Fukuoka Japan.ORCID https://orcid.org/0000-0001-8768-5388
Satoshi ToshiyamaDepartment of Upper Gastrointestinal Surgery Kansai Medical University Moriguchi City Japan.
Makoto YamasakiDepartment of Upper Gastrointestinal Surgery Kansai Medical University Moriguchi City Japan.
Masaki KaiboriDepartment of Hepatobiliary Surgery Kansai Medical University Hirakata Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gemcitabine plus cisplatin (GC) has been the global standard for advanced biliary tract cancer (BTC). The triplet regimen gemcitabine-cisplatin-S-1 (GCS) demonstrated superiority in the MITSUBA trial, but its real-world effectiveness remains unclear. We compared survival outcomes of GCS versus GC, focusing on conversion surgery (CS). Methods: We retrospectively analyzed 542 patients with unresectable BTC treated between 2017 and 2024 at 19 Japanese institutions. Patients received GC ( Results: Patients treated with GCS achieved greater tumor shrinkage (median -23.0% vs. -10.0%, Conclusions: Treatment with GCS was associated with longer survival compared with GC in unresectable BTC, alongside a higher rate of conversion surgery, which was associated with favorable long-term outcomes.

Indexed as

biliary tract neoplasmscholangiocarcinomacisplatingemcitabineTegafur Gimeracil Oteracil potassium (S‐1)

Identifiers

PMID42395119
PMCPMC13326820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.